These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 21507361)

  • 1. DNA methylation changes in cancer.
    Toyota M; Yamamoto E
    Prog Mol Biol Transl Sci; 2011; 101():447-57. PubMed ID: 21507361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic drivers of genetic alterations.
    Toyota M; Suzuki H
    Adv Genet; 2010; 70():309-23. PubMed ID: 20920753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CpG island methylator phenotype correlates with long-range epigenetic silencing in colorectal cancer.
    Karpinski P; Ramsey D; Grzebieniak Z; Sasiadek MM; Blin N
    Mol Cancer Res; 2008 Apr; 6(4):585-91. PubMed ID: 18403637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of DNA hypermethylation in human neoplasia.
    Toyota M; Issa JP
    Electrophoresis; 2000 Jan; 21(2):329-33. PubMed ID: 10675010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting aberrant chromatin structure in colorectal carcinomas.
    Konishi K; Issa JP
    Cancer J; 2007; 13(1):49-55. PubMed ID: 17464246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CpG island methylator phenotype (CIMP) in cancer: causes and implications.
    Teodoridis JM; Hardie C; Brown R
    Cancer Lett; 2008 Sep; 268(2):177-86. PubMed ID: 18471961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.
    Abbosh PH; Montgomery JS; Starkey JA; Novotny M; Zuhowski EG; Egorin MJ; Moseman AP; Golas A; Brannon KM; Balch C; Huang TH; Nephew KP
    Cancer Res; 2006 Jun; 66(11):5582-91. PubMed ID: 16740693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CpG island methylator phenotypes in aging and cancer.
    Toyota M; Issa JP
    Semin Cancer Biol; 1999 Oct; 9(5):349-57. PubMed ID: 10547343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic changes in cancer.
    Grønbaek K; Hother C; Jones PA
    APMIS; 2007 Oct; 115(10):1039-59. PubMed ID: 18042143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations of DNA methylation and clinicopathological diversity of human cancers.
    Kanai Y
    Pathol Int; 2008 Sep; 58(9):544-58. PubMed ID: 18801069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state.
    Kanai Y; Hirohashi S
    Carcinogenesis; 2007 Dec; 28(12):2434-42. PubMed ID: 17893234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker.
    Teodoridis JM; Strathdee G; Brown R
    Drug Resist Updat; 2004; 7(4-5):267-78. PubMed ID: 15533764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus.
    Kusano M; Toyota M; Suzuki H; Akino K; Aoki F; Fujita M; Hosokawa M; Shinomura Y; Imai K; Tokino T
    Cancer; 2006 Apr; 106(7):1467-79. PubMed ID: 16518809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA methylation in ovarian cancer. II. Expression of DNA methyltransferases in ovarian cancer cell lines and normal ovarian epithelial cells.
    Ahluwalia A; Hurteau JA; Bigsby RM; Nephew KP
    Gynecol Oncol; 2001 Aug; 82(2):299-304. PubMed ID: 11531283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells.
    Stirzaker C; Song JZ; Davidson B; Clark SJ
    Cancer Res; 2004 Jun; 64(11):3871-7. PubMed ID: 15172996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetics and cancer treatment.
    Kristensen LS; Nielsen HM; Hansen LL
    Eur J Pharmacol; 2009 Dec; 625(1-3):131-42. PubMed ID: 19836388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promoter methylation status of multiple genes in uveal melanoma.
    Merhavi E; Cohen Y; Avraham BC; Frenkel S; Chowers I; Pe'er J; Goldenberg-Cohen N
    Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4403-6. PubMed ID: 17898258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic changes in solid and hematopoietic tumors.
    Toyota M; Issa JP
    Semin Oncol; 2005 Oct; 32(5):521-30. PubMed ID: 16210093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells.
    Robert MF; Morin S; Beaulieu N; Gauthier F; Chute IC; Barsalou A; MacLeod AR
    Nat Genet; 2003 Jan; 33(1):61-5. PubMed ID: 12496760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA methylation and gene silencing in cancer: which is the guilty party?
    Clark SJ; Melki J
    Oncogene; 2002 Aug; 21(35):5380-7. PubMed ID: 12154400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.